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Abstract
Background: A vast diversity of microbes colonizes in the human gastrointestinal tract, referred to intestinal
microbiota. Microbiota and products thereof are indispensable for shaping the development and function of host
innate immune system, thereby exerting multifaceted impacts in gut health.
Methods: This paper reviews the effects on immunity of gut microbe-derived nucleic acids, and gut microbial
metabolites, as well as the involvement of commensals in the gut homeostasis. We focus on the recent findings
with an intention to illuminate the mechanisms by which the microbiota and products thereof are interacting with
host immunity, as well as to scrutinize imbalanced gut microbiota (dysbiosis) which lead to autoimmune disorders
including inflammatory bowel disease (IBD), Type 1 diabetes (T1D) and systemic immune syndromes such as
rheumatoid arthritis (RA).
Results: In addition to their well-recognized benefits in the gut such as occupation of ecological niches and
competition with pathogens, commensal bacteria have been shown to strengthen the gut barrier and to exert
immunomodulatory actions within the gut and beyond. It has been realized that impaired intestinal microbiota not
only contribute to gut diseases but also are inextricably linked to metabolic disorders and even brain dysfunction.
Conclusions: A better understanding of the mutual interactions of the microbiota and host immune system, would
shed light on our endeavors of disease prevention and broaden the path to our discovery of immune intervention
targets for disease treatment.
Keywords: Intestinal microbiota, Gut homeostasis, Immune responses, Regulatory T cells (Tregs), Dendritic cells
(DCs), Metabolic disorder
Background
Human gastrointestinal tract is known to host trillions
of microbes [1, 2], the number of which reaches approxi-
mately 1014 cells in the entire gut of a healthy individual
[1]. Amongst these resident gut microbes, 4000 strains
are present constituting the intestinal microbiota [3].
Through co-evolution, the host has not only tolerated but
also evolved to necessitate the colonization by beneficial
microbes, termed commensals, for multifaceted aspects
of immune development and function [4]. Defects in
mucosal tolerance are believed to cause human disor-
ders including inflammatory bowel disease (IBD) exem-
plified by Crohn’s disease and ulcerative colitis [5].
As the first line defense of host against pathogens, innate
immune responses rely on a family of receptors known as
pattern recognition receptors (PRRs) including Toll-like re-
ceptors (TLRs), and nucleotide-binding oligomerization
domain-like (NOD-like) receptors. TLRs are key innate im-
mune receptors to perceive pathogen-associated molecular
patterns (PAMPs), which are specific pathogenic “molecular
signature” [6]. Subsequent to sensing microbial PAMPs,
TLRs enable the initiation of inflammatory responses
and eventually eliminate the pathogenic invaders. The
phenomenon that both commensals and pathogenic mi-
crobes can interact with host immune system through
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similar conserved ligands —PAMPs, drives us to address
such question as to how host immune system differentiates
pathogens from commensals at the intestinal mucosal
interface exposed to continuous microbial stimuli.
Severe host tissue damage may be resulted from immune
hypersensitivity towards intestinal flora or dietary nutrients.
To circumvent this, the host implements a variety of regu-
latory mechanisms for organ homeostasis maintenance.
Regulatory T cells (Tregs) serve one such mechanism as
evidenced by the otherwise catastrophic consequences
under genetic/or physical ablation of the Treg population
[7]. Tregs are the specialized T cells with immunosuppres-
sive activity through an array of mechanisms that influence
both dendritic cells (DCs) and effector cells [8].
DCs, constituting the first point of contact between
gut commensals and mammalian immune system [9],
are central to harmonizing the host tolerance (to self-
antigens) with host immunity (to pathogens) in the per-
ipheral lymphoid tissues [10]. DCs are able to present
innocuous self and non-self antigens in a manner that
promotes tolerance [8]. The predominant mechanism by
which DCs induce and maintain peripheral tolerance
involves the generation of Tregs from naïve T cells, the
expansion of pre-existing Tregs, the production of IL-10
and other immunomodulatory cytokines, and the pro-
motion of T cell anergy or depletion [11, 12].
Immature DCs (iDCs), present in all peripheral tissues,
are capable of acquiring antigenic material from their
microenvironment, but are poorly immunogenic (also
called tolergenic). The pathogenic microbial signals can
be sensed by iDCs for propelling their conversion into
mature DCs, which, present within secondary lymphoid
organs, could obtain the capacity of promoting T cell
immunity but lose the capacity of antigen uptake [13].
In short, DCs are able to trigger seemingly opposite
states —— immunity and tolerance depending on differ-
ent microenvironment conditions [13]. Intestinal DCs,
together with macrophages and epithelial cells, may
serve as sentinels in the microbial milieu of intestine.
The exceptional characteristic of intestinal microenvir-
onment necessitates host immune system not only to
avoid the hyper-immune reactivity to the gut lumen
laden with commensals and dietary components etc,
but also to retain the capacity of fighting pathogenic
microbes.
Extensive studies in germ-free (GF) mice, in the past
decades, have demonstrated an indispensable role of
microbiota in shaping host intestine immune system
[14]. In contrast to conventionally raised mice, GF mice
have hypoplastic Peyer’s patches, decreased numbers in
IgA-secreting plasma cells and lamina propria CD4+ T
cells, relatively structureless secondary lymphoid tissues
(i.e. spleen and peripheral lymph nodes) and other im-
munologic defects. Inoculation of a healthy murine
commensal microbiota into GF mice has been found to
reverse these immunologic deficiencies [14]. In addition
to immunostimulatory effects as afore-described, certain
members of intestine microbiota may exert immuno-
modulatory actions that involve reversible alterations in
differentiation/or effector function of host immune cell
subsets, exemplified by segmented filamentous bacteria
(SFB), Bacteroides fragilis, Clostridia XIVa and IV.
This aspect will be reviewed in details in the Section
of “Commensals and gut homeostasis”. Furthermore,
compelling evidence with microbiota-derived metabo-
lites, mainly referring to small-molecule constituents
such as short-chain fatty acids (SCFAs) and quorum
sensing signals, has established the importance of
chemical signaling in communicating microbial rich-
ness and composition with host. And microbial me-
tabolites can be sensed by host immune system in
addition to PAMPs, which in turn influences host
immune responses. Butyrate, a kind of microbiota-
originated SCFAs containing four carbons, has been
recently reported to have immunomodulatory effects
on intestinal macrophages and thereby conferring
them hyporesponsive to commensal microbiota resid-
ing in the colon [15]. Notwithstanding, the underlying
mechanisms as to how intestinal microbiota, as a
whole, educates host immune system within the gut
and beyond, as well as the identification of bacterial
species-specific contribution during the microbiota-
host immunity interaction still await to be elucidated.
As a paradigm of bacterial strain-specific molecules,
butyrate acts as HDAC inhibitors and ligands for G-
protein-coupled receptors (GPCRs) and is considered
as a crucial signaling molecule affecting host immune
responses [16].
Majority of human lymphoid tissue is located within
the lining of the major tracts that are predominant
entry sites of microbes into host, referring to respira-
tory, gastrointestinal (GI) and genitourinary tracts,
which are collectively termed the mucosa-associated
lymphoid tissues. The intestinal mucosa appears to be
the largest surface within human body facing enor-
mous amounts of microbial antigens either resident
or ingested. This review summarizes the recent ad-
vances in the field of microbiota and their products
interacting with the GI mucosal immune system. We
aim to provide an update into the research progress
relevant to the possible contributions of microbiota
and their products to the intestinal homeostasis main-
tenance, which, hopefully, would facilitate the virtual
discovery and insightful design of promising thera-
peutic targets for treatment of human disorders in as-
sociation with intestinal dysbiosis and autoimmunity,
such as type 1 diabetes (T1D), systemic immune syn-
dromes (i.e. IBD etc.) and even colorectal cancer.
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Effects of gut microbe-derived nucleic acids on immunity
TLR9 senses unmethylated cytidine-phosphate-guanosine
(CpG) motifs of DNA
Host cells can initiate innate immune signaling upon
recognition of PAMPs (viz. conserved structures in
pathogenic microbes), of which nucleic acids are key
structures. The receptors for foreign nucleic acids in-
volve members of TLRs including TLR3, TLR7, TLR8,
and TLR9, and intracellular DNA sensors [17]. The endo-
somal localizations of TLR3 [activated by double-stranded
(ds) RNA], TLR7 and 8 [activated by single-stranded (ss)
RNA], TLR9 [activated by CpG motifs within ssDNA]
reflect the protective mechanism whereby unwanted inter-
actions of TLRs with self-nucleic acids could be cir-
cumvented. Another protective mechanism may involve
modifications of mammalian nucleic acids [18]. Detec-
tion of intracellular pathogens is achieved by those
endosomally-expressed TLR3, and TLRs 7–9, eventu-
ally leading to the clearance of pathogens.
Among those TLRs in association with intracellular
invaders, TLR9 and signaling thereof are more exten-
sively investigated than others. Unmethylated CpG dinu-
cleotides that are enriched in prokaryotic DNAs of
intestinal flora, can be sensed by TLR9. Constitutive gut
flora DNA sensing is found to modulate the equilibrium
between regulatory and effector T cells in the murine GI
tract, suggesting the gut flora DNA as an immunological
adjuvant [19]. Moreover, unmethylated CpG has been
reported of immunostimulatory effect in mice and other
mammals, as well as in-vitro human cell lines [20, 21].
Bacterial DNA and synthetic oligonucleotiodes (ODN),
which contain unmethylated CpG in common, are able
to activate the innate and adaptive immune system via
plasmacytoid dendritic cells (pDCs) and macrophages in
mammals [22].
Upon CpG stimulation, a signaling cascade is elicited
that leads to the production of proinflammatory cyto-
kines and type I IFNs [23, 24], the latter being predom-
inantly secreted by pDC. These soluble components
coordinate early innate and sequential adaptive immune
responses [24]. The tissue specificity and cellular pattern
of TLR expression are believed to vary with different
species, even in mammals. For instance, murine TLR9 is
expressed not only in pDC and B cells as human TLR9,
but also in macrophages and myeloid DCs as well [21].
Thus one should be cautious with predicting the effects
of TLR9 activation on humans by extrapolating from
murine data.
TLR9 signaling and autoimmunity
Several lines of evidence have revealed inappropriate
activations of TLR7, TLR8, and TLR9 in systemic lupus
erythematosus (SLE) and several other autoimmune
diseases. T and B cells specific for self-antigens can be
detected in healthy individuals but do not suffice to
provoke the development of autoimmune diseases. In
contrast, SLE individuals are reported to suffer from im-
paired clearance of apoptotic cells and increased circu-
lating levels of nucleosomes [18]. CpG motifs derived
from apoptotic debris could activate TLR9, notably
under the circumstance that they are converted into im-
mune complexes with pre-existing auto-antibodies,
followed by B cells stimulation through both TLR9 and
B-cell receptor, which in turn leads to autoimmunity
and systemic autoimmune disease [25]. In such SLE
individuals, host DNA/antibody complexes trigger and
sustain a pDC- and B cell-mediated immune response
[26, 27], which indicates self-DNA as damage-associated
molecular pattern (DAMP) modulating self-destructive
chronic immune activation [28].
Studies have characterized several proteins as inter-
mediate cofactors (chaperones) to initiate the TLR9 acti-
vation upon perception of CpG, which include human
cathelicidin LL-37 and the high mobility group box
(HMGB). Cathelicidin LL-37, a cationic peptide with
wide-spectrum antimicrobial activities, is chemotactic
for neutrophils, mast cells, monocytes, and T cells [29].
In psoriasis patients LL-37 may serve as a converter of
self-DNA into pathogenic ligand due to its binding to
self-DNA. The resultant LL37-DNA complex is found to
promote the endocytosis pathway and to sustain TLR9
activation by modifying the interaction with DNA [30].
Accordingly, LL37 facilitates TLR9 activation of self-
DNA and synthetic CpG DNA. CpG islands under
study were demonstrated to be immunostimulatory
when coupled with human cathelicidin LL-37, strongly
suggesting the critical role of LL-37 in the immunosti-
mulatory effects of CpG motif-containing mtDNA
fragments [24].
TLR9 recognizes not only CpG motifs “embedded” in
bacterial DNA but also similar motifs in vertebrate
DNA, pinpointing that the same receptor perceives
PAMP and DAMP, which complies with the notion that
the immune system is more concerned with entities that
do damage than those that are foreign [31]. It also indi-
cates that similarities exist between pathogen-induced
responses and non-infectious inflammatory responses
[32]. CpG motifs in prokaryotic DNA are known to be
20 times more enriched than those in mammalian DNA;
and even found in the mammalian genomic DNA, they
are specifically methylated. MtDNA is predominantly
unmethylated in view of its prokaryotic origin based on
endosymbiosis theory [33]. Once eukaryotic cells undergo
apoptosis, necrosis, necroptosis and cell death in associ-
ation with autophagy, mtDNA is released acting as
mtDAMP. On the other hand, neutrophils, basophils and
eosinophils, upon stimulation, can release extracellular
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traps of mtDNA or genomic DNA. These traps contain
such antimicrobial peptides as cathelicidins and cell-
specific proteases. A growing body of evidence has re-
vealed that elevated levels of circulating mtDNA may
cause systemic inflammatory response syndrome in
trauma patients and also act as a trigger of neurodegener-
ation [34, 35]. The pDC may be stimulated by an influx of
neutrophils releasing extracellular traps of DNA [36], and
are subsequently recruited to the colorectum and gut
mucosa [37, 38]. Accordingly, fragmented mtDNA bearing
CpG motif may contribute to driving a Th1 polarization in
autoimmune disorder and chronic viral diseases [24].
TLR9 signaling and gut cancinoma
CpG-mediated TLR9 activation may serve as a new
therapeutic target for several cancerous conditions. The
potentials of TLR9 agonists (synthetic CpG ODN) in
therapeutic applications for infectious diseases, cancer
and asthma/allergy have been reviewed elsewhere [21].
Recent studies have determined the association of
TLR9 polymorphisms with human susceptibility to gas-
tric carcinoma and its prognosis in Chinese population
[39]. The work by Wang et al strongly suggests that
TLR9-1486C carriers are associated with an increased
risk and poor prognosis of gastric carcinoma in human
[39]. Another independent group has shown the cell-
invasion-inducing potential of short DNA sequences and
bacterial DNAs in tested cell lines including human
MDA-MB-231 breast cancer, OE33 esophageal ad-
enocarcinoma, AGS gastric adenocarcinoma and Caco-2
colon carcinoma [40]. An array of DNA ligands was
investigated including short DNA sequences such as
CpG-ODN M362, 9-mer (hairpin), human telomeric se-
quence h-Tel22 G-quadruplex, and bacterial DNAs de-
rived from Escherichia coli and Helicobacter pylori [40].
DNA-induced invasion was shown to be suppressed by a
broad-spectrum matrix metalloproteinase (MMP) inhibi-
tor and in part by chloroquine, suggestive of its medi-
ation through endosomal signaling, TLR9 and MMP
activation. This notion is reminiscent of the association
of MMP overexpression with breast cancer brain metas-
tasis [41]. The work by Kauppila et al. strongly suggests
that bacterial DNAs could act as endogenous and
invasion-triggering TLR9 ligands and thereby accelerat-
ing local progression and metastasis of carcinoma in the
digestive tract [40].
Immunmodulatory effects of gut microbiota-derived DNA
It awaits elucidating how commensals communicate
with host cells to ensure immune homeostasis. As widely
known, commensals contain abundant oligodeoxynu-
cleotides with CpG motifs (CpG-ODN), the latter of
which has been shown to co-stimulate T cells analogous
to that achieved by CD28 stimulation, irrespective of
antigen-presenting cells (APCs). The inherent attribute
of CpG-ODN towards T cells may contribute to the
adjuvanticity potency of microbital DNA and CpG-ODN
on T-cell-mediated immune responses [42].
Recent work with gut commensals demonstrated gut-
floral-derived DNA (gfDNA) as an intrinsic adjuvant to
prime intestinal immune responses, in which TLR9 signal-
ing is involved [19]. TLR9 signaling was found to lower
the activation threshold by negative and positive expan-
sions of Treg and Teff (effector T) cells, respectively, in
the gut, and was liable to development of protective re-
sponses upon oral infection. Thus gfDNA is strongly
suggested to be a natural adjuvant for initiating protective
immune responses via modulation of Treg/Teff cell ratio
at sites of mucosal challenge, which offers promising
therapeutic strategy against oral infection [19].
Another independent work with suppressive DNA
motifs of the commensal origin showed that these
oligonucleotides could contribute to the hierarchy of
commensal-derived signals and thereby facilitating the
maintenance of gut immune homeostasis [43]. Com-
mensal DNA was previously demonstrated to promote
intestinal immunity. It has been unveiled that the
bacterial species-specific immunomodulatory capacity
of DNA is correlated with the frequency of motifs
exerting immunosuppressive action [43]. For instance,
DNAs of Lactobacillus species, together with those of
various probiotics, are known to be enriched in sup-
pressive motifs capable of inhibiting DC activation
within lamina propria of intestine. In addition, im-
munosuppressive oligonucleotides could sustain Treg
cell conversion during inflammation, and regulate
pathogen-triggered immunopathology and colitis. Collect-
ively, these data pinpoint the suppressive DNA motifs to
be a molecular ligand typical of commensals, supporting
the notion that a balance between stimulatory and re-
gulatory DNA motifs may contribute to the induction of
controlled immune responses in the GI tract, thereby
influencing the gut homeostasis maintenance [43]. The
above-mentioned findings suggested that the endogenous
regulatory DNA motifs abundant in specific commensal
bacteria could serve as the core of DNA-based vaccines of
therapeutic value.
Effects of gut microbial metabolites on immunity
Gut microbiota-released metabolites, which are interme-
diates and/or end products of dietary constituents by
commensal metabolism, may exert indispensable actions
on host immunity and health [44]. Some of anaerobic
gut microbes have the potential of converting dietary
carbohydrates into organic acids including lactate, and
short-chain fatty acids (SCFAs), the latter principally re-
ferring to acetate, propionate and butyrate. In mammals
butyrate serves as a predominant energy substrate for
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colonocytes and enterocytes [45, 46]. Propionate is
primarily absorbed by the liver while acetate is released
into peripheral tissues [46]. In human gut, bacteria of
the Bacteroidetes phylum secrete high levels of acetate
and propionate whereas those of the Firmicutes phylum
generate large amounts of butyrate [47]. Commensurate
with increasing interests of SCFAs pertinent to Bacteroi-
detes and Clostridia phylum in the human gut [48],
some other metabolites may serve as signaling molecules
for inter-bacterial communication and quorum sensing.
Among them are bacterial QS signals (also called autoin-
ducers, or pheromones) and poly-γ-glutamic acid, the
latter of which was recently characterized in Bacillus
subtilis. Significant progress has been made to broaden
our understanding about the modulatory effects of these
gut microbial metabolites on host immunity (Fig. 1).
Short-chain fatty acids (SCFAs)
A growing body of evidence has revealed SCFAs as key
metabolic and immune mediators [49, 50]. Distinct
bioactivities of SCFAs may be attributed to their rapid
absorption, with approximately only 5% being excreted
through faeces. For instance, apart from the predominant
energy source for the colonocytes, butyrate is found to be
anti-inflammatory mainly through the suppression of NF-
κB [51], be capable of altering the composition of the
mucus layer by inducing mucin synthesis [52–54] and of
exerting anti-cancer activities [55, 56]. Functional links are
thus proposed among the dietary components, the gut
microbiota composition and host immune homeostasis,
inferring that different dietary preference may, at least
partially, contribute to the racial and regional divergence
in human population susceptibility to autoimmune disor-
ders, inflammatory diseases and cancers.
Further studies with the experimental models of colitis
and arthritis, have demonstrated that SCFAs could bind the
GPR43 (G protein-coupled receptor 43, also known as free
fatty acid receptor 2, FFAR2) and thus repressing the
inflammation via interaction with FFAR2-expressing neu-
trophils [49, 57]. SCFAs, as endogenous ligands for the G-
protein-coupled receptors GPR41 (viz. FFAR3) and GPR43
(viz. FFAR2), have been illustrated to mediate an array of
Fig. 1 Gut microbial metabolites and host immune responses. CSF: Competence and sporulation factor; IECs: Intestinal epithelial cells. G− and G+
indicate gram-negative and -positive bacteria, respectively
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metabolic processes such as the synthesis of glucagon-like
peptide 1 in the enteroendocrine cells [45, 58].
There is ample evidence that SCFAs can activate
GPR41 and GPR43 expressions in intestinal epithelial
cells (ECs), leading to mitogen-activated protein kinase
(MAPK) signaling, and production of chemokines and
cytokines, which mediates protective immune response
and tissue inflammation in mice [59]. The murine intes-
tinal immune responses were investigated against im-
munological challenges including breach of the gut
barrier (ethanol administration), 2, 4, 6-trinitrobenzene
sulfonic-acid (TNBS) treatment, and infection of Citro-
bacter rodentium. GPR41 −/− and GPR43 −/− mice
underwent the reduced inflammatory responses in the
colon as indicated by low induction of inflammatory
chemokines, cytokines and leukocyte infiltration. Fur-
thermore, mice devoid of GPR41 or GPR43 failed to
mount a normal Th1 response to TNBS treatment,
which was in line with the notion derived from the etha-
nol administration that SCFA signals are indispensable
for optimal acute inflammatory responses in the gut.
The results clearly delineated beneficial roles of SCFAs
and their receptors in conditioning gut ECs to mount
prompt immunity in response to immunological stimuli
in a GPR41- and GPR43-dependent manner [59].
Butyrate is widely recognized to be capable of inhibit-
ing the expression of pro-inflammatory cytokines such
as IL-12 and TNF-α [60, 61]. Butyrate is also demon-
strated to induce the expression of intestinal epithelial
heat shock protein (HSP) 25 and 72. Moreover, HSP 25
and 72, in addition to molecular chaperones, have been
documented to be down-regulatory towards the expres-
sion of pro-inflammatory cytokines under stress such as
infection and inflammation in the colon [62]. In con-
trast, either a fermentable fiber-lacking diet or chemical
challenges mainly affecting anaerobic bacteria (by metro-
nidazole administration), could manifestly decrease HSP
expression in intestinal epithelia. In view of HSPs’ par-
ticipation in the cellular responses to stressful factors
and their hyper-expressions under inflammatory condi-
tions, it has been postulated that butyrate may be associ-
ated with anti-inflammation.
Butyrate is known for its anti-inflammatory activities and
thereby impacting host colon health [63, 64]. Accumulating
evidence has shown that butyrate could attenuate bacterial
translocation across epithelia under metabolic stress [65],
and enhance the gut barrier via augmenting tight junction
assembly [66]. In addition, a randomized, double-blind clin-
ical trial has revealed the effects of butyrate as an adjunct
therapy in combination with antibiotics on the treatment of
shigellosis patients [67].
Propionate, derived from gut microbial fermentation
of dietary inulin-type fructans (ITF, also known as a
prebiotic nutrient), is reported to alleviate liver cancer
cell proliferation [68]. As previously documented, ITF
can alter the gut microbiota composition and activity
[69]. In order to elucidate how ITF influenced neoplasm
proliferation beyond the gut, researchers used mice
transplanted with Bcr-Abl-transfected BaF3 cells receiv-
ing ITF supplementation. Ectopically Bcr-Abl-expressed
pro-B murine BaF3 cells were chosen as the model
under study because of their invasive and proliferative
potentials in the lymphoid organs, such as liver tissues
that could actively absorb the gut-originated SCFAs
[70, 71]. The authors, by using gut microbiota ana-
lysis, in-vitro and in-vivo cell proliferation assays as
well as serum SCFA quantitation, have in-vivo dem-
onstrated that ITF attenuates hepatic BaF3 cell infil-
tration, increases propionate in the portal vein and
lessens systemic inflammation. They have also in-vitro
shown that propionate decreases BaF3 cell prolifera-
tion through a cAMP-dependent pathway and that
activation of FFAR2 (viz. GPR43) alters proliferation
of BaF3 and other human cancer cell lines. These
data represent the first report that gut microbiotal
conversion of prebiotic nutrients (ITF herein) into
propionate could inhibit malignant cell proliferation
beyond the gut.
Accumulating evidence indicates that a diverse range
of commensal microbes could shape the gut immune
system. It has been reported that colonization with
Clostridia induces differentiation of peripheral Treg cells
that have a critical role in the suppression of inflamma-
tory and allergic responses [72, 73]. However, the mo-
lecular cues of such microbe-mediated Treg induction
remain unknown. Two recent Nature papers demon-
strate that the colonic microbial fermentation product
butyrate tremendously enhances the differentiation of
colonic Treg cells and thus meliorates colitis, which is
dependent on an augmented histone H3 acetylation at
the Foxp3 promoter [74, 75]. As widely known, butyrate,
and, to a lesser degree, propionate, are histone deacety-
lase (HDAC) inhibitors that epigenetically regulate gene
expression. In the above-mentioned studies, propionate
shows a moderate effect on extrathymic Treg cell induc-
tion. These findings suggest butyrate to be an inducer of
extrathymic Treg cells in the colonic mucosa, and pro-
vide molecular insight into how a metabolite of gut
microbiotal origin can modulate the cross-talk between
commensal community and host immune system for gut
homeostasis maintenance.
SCFAs including propionate and butyrate can activate
gluconeogenesis (IGN) via complementary mechanisms.
Intestinal IGN is known to mediate host glucose and en-
ergy homeostasis [45]. De Vadder et al. [45] illustrated
that butyrate was able to activate IGN gene expression
via a cAMP-dependent mechanism, whereas propionate,
a substrate of IGN as well, could stimulate IGN gene
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expression via a gut-brain neural circuit involving the
fatty acid receptor FFAR3. Conversely, in spite of similar
modifications in gut microbiota composition, the SCFA-
induced positive effects on body weight and glucose
control observed with normal mice are abrogated in
IGN-deficient mice. Altogether, regulation of IGN is
essential for the metabolically beneficial roles of SCFAs
and soluble fiber [45]. Despite the metabolic benefits
being ascribed to fiber-rich diets in the past decades,
this work unravels that IGN may contribute to favor-
able actions of SCFAs on body weight and glucose
control [45].
Quorum sensing signals
Quorum sensing (QS), one of bacterial regulatory mech-
anisms to perceive and promote synchronized behaviors,
relies on bacterial population density. This cell density-
dependent system operates through the secreted small-
molecular compounds called QS signals [76], which is
utilized by pathogens to initiate the expression of
virulence factors and biofilm formation and thereby
facilitating their invasion and colonization into hosts
[77, 78]. Evidence has revealed that such QS signals may
also act as an important anti-immune arsenal and key
mediators of inter-kingdom (host-bacteria) antagonistic
relations [78, 79].
Host responses to pathogens involve the innate and
adaptive immune reactions, both of which are commit-
ted to limit diffusion of the invaders. Notwithstanding,
in order to control the probable detrimental conse-
quences of pathogens, a variety of host regulatory ele-
ments may be operative including Tregs. Mucosal
CD103+ DCs are known contributors to the conversion
of Tregs depended on TGF-β and retinoic acid [80, 81].
Pseudomonas aeruginosa, an opportunistic pathogen,
is a causative agent for diseases like cystic fibrosis, and
often accounts for life-threatening nosocomial infections
among immunocompromised individuals [82, 83]. P.
aeruginosa produces more than one class of QS signals
to coordinate its pathogenesis. In P. aeruginosa two
chemically distinct classes of QS signals are identified to
be N-acylhomoserine lactones (AHLs) and 4-hydroxy-2-
alkylquinolines (HAQs) [84, 85]. Among them N-(3-oxo-
dodecanoyl)-L-homoserine lactone (3O-C12-HSL) is
produced via the LasI synthase and sensed via the tran-
scriptional activator LasR, which in turn modulates the
expression of virulence factors and enhances biofilm
maturation [86]. Ample evidence has revealed the in-
volvement of P. aeruginosa 3O-C12-HSL in both es-
tablishment of bacterial pathogenesis and subversion of
host immune system, suggestive of its immunosuppres-
sive effects [86]. Kravchenko et al. [87] reported that the
bacterial (P. aeruginosa) 3O-C12-HSL could selectively
impair the regulation of NF-κB functions in activated
mammalian cells, specifically dampening the induction
of NF-κB–responsive genes that encode inflammatory
cytokines and other immune modulators [87]. Their re-
sults demonstrate, for the first time, the anti-inflammatory
effects of bacterial 3O-C12-HSL via in-vivo modula-
tion of host NF-κB pathway, which likely contributes
to the establishment and maintenance of local persist-
ent infection of bacteria.
In addition to the well-studied AHLs, HAQs-the
second class of P. aeruginosa QS signals encompass the
derivatives of 4-hydroxy-2-heptylquinoline (HHQ) and
the corresponding dihydroxylated derivatives such as 2-
heptyl-3,4-dihydroxyquinoline (PQS, pseudomonas quin-
olone signal) [84]. Regulatory effects of HAQs were
investigated in the host innate immunity using a wild-
type (PA14) and two mutants of P. aeruginosa. Results
have unraveled that bacterial HHQ and PQS could
actively inhibit innate immune responses in vitro and in
vivo via the NF-κB pathway. Specifically, HHQ and PQS
were found to attenuate the NF-κB binding to its bind-
ing sites and to downregulate the expression of NF-κB
target genes, and PQS was also observed to delay the
degradation of IκB (inhibitor of κB) [84]. The above-
mentioned work provides a paradigm that bacterial
suppression of host immune system by QS signals is an
effective strategy for bacterial immune evasion and sur-
vival in the hostile host environment.
Mounting evidence has shown the effects of bacterial
AHLs on neutrophils, macrophages and other mammalian
cells. Human neutrophils are found to be attracted by QS
molecules 3O-C12-HSL and -C10-HSL to the sites of infec-
tion and developing biofilms [88]. It appears that human
primary neutrophils can strongly be stimulated by 3O-
C12-HSL and -C10-HSL in a dose-dependent manner, with
no distinct effects being displayed in the case of C4-HSL
supplementation [88]. Mechanisms were further explored
whereby these QS signals were able to induce chemotaxis
in human neutrophils. Results revealed that these long-
and middle-chain fatty acid AHLs could act through Ca
mobilization and actin remodeling, suggesting AHLs as
key mediators during the recruitment of inflammatory
cells to the infection sites [88].
Given the human phagocytic cell-activating and in-
vitro polymorphonuclear neutrophils (PMN)-chemotac-
tic potentials of 3O-C12-HSL, further studies have been
conducted to investigate how 3O-C12-HSL activates
neutrophils and to analyze signaling pathways relevant
to migration [89]. The work focused on the mitogen
activated protein (MAP) kinase p38 because an inhibitor
of p38 (SB203580) was known to prevent the 3O-
C12-HSL-mediated chemotaxis. Data showed that 3O-
C12-HSL swiftly induced activation of the MAP kinase
p38, which in turn activated MAPKAP-Kinase 2 (MK2)
and its target, the leukocyte specific protein1 (LSP1), the
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latter being able to directly interact with F-actin. LSP1
was activated (phosphorylated) and co-localized with F-
actin in polarized PMN upon exposure to 3O-C12-HSL,
suggesting that: (1) 3O-C12-HSL might induce p38-
dependent chemotaxis; (2) the p38 signaling is function-
ally linked to the cytoskeleton dynamics via LSP1 [89].
QS molecule 3O-C12-HSL plays critical roles in not
only inter-bacterial communication but inter-kingdom
signaling. It is believed that the ability of 3O-C12-HSL to
downregulate the production of TNF-α (key proinflam-
matory cytokine) in stimulated macrophages may con-
tribute to the establishment of chronic infections by
such opportunistic bacteria as P. aeruginosa [90]. The
authors (2013) showed that, in contrast to the suppres-
sion of TNF-α secretion, 3O-C12-HSL could amplify the
production of major anti-inflammatory cytokine IL-10 in
lipopolysaccharide (LPS)-stimulated murine RAW264.7
macrophages as well as peritoneal macrophages [90].
Furthermore, 3O-C12-HSL could increase IL-10 mRNA
levels and IL-10 promoter reporter activity in LPS-
stimulated RAW264.7 macrophages, indicating its mod-
ulatory effects on IL-10 at the transcriptional level.
Finally, 3O-C12-HSL could remarkably potentiate the
LPS-stimulated NF-κB DNA-binding levels and prolong
p38 MAPK phosphorylation in RAW264.7 macrophages,
suggesting that the increased transcriptional activity of
NF-κB and/or p38-activated transcription factors might
upregulate IL-10 production in macrophages upon
exposure to both LPS and 3O-C12-HSL. These findings
collectively unravel another circuit of the complex array
of host transitions whereby opportunistic bacteria down-
regulate host immune responses to thrive and to estab-
lish a chronic infection.
In addition to QS signals produced by G− bacteria
such as P. aeruginosa, those derived from Gram-positive
(G+) bacteria are found to exert immunomodulatory
actions on hosts [91]. A kind of QS signal from Bacillus
subtilis, also termed competence and sporulation factor
(CSF), has been demonstrated to be stimulant of the key
survival pathways including p38 MAP kinase and pro-
tein kinase B (Akt) in mammalian intestinal epithelial
cells [92]. Moreover, CSF seems to induce HSPs for pro-
tecting intestinal epithelial cells from oxidant stress and
for avoiding the loss of barrier function. The intestinal
homeostasis-maintenance ability of CSF is found to rely
on its absorption by an apical membrane organic cation
transporter-2 (OCTN2). Accordingly, the finding of
OCTN2-mediated CSF transport unravels a new aspect
of host–bacterial interactions that facilitates host moni-
toring and responding to behavioral or compositional
changes of colonic microbiota. More recently, the same
group investigated the B. subtilis-originated CSF by
determining its impacts on attenuating intestinal inflam-
mation. Results showed that anti-inflammatory effect of
CSF was mediated by the downregulation of pro-
inflammatory mediators (IL-4, IL-6 and CXCL-1), the
upregulation of anti-inflammatory cytokine IL-10, and
the induction of cytoprotective protein HSPs in Caco-2/
bbe cells (human intestinal epithelial cell). The histo-
logical score of intestinal inflammation in 2% dextran
sodium sulfate (DSS)-treated mice under the administra-
tion of 10nM CSF was distinctly lower than that in
control mice. Additionally, CSF was observed to be able
to ameliorate the survival ratio of mice formerly treated
with a lethal dose of DSS. It is thus concluded that CSF
may represent one of potential therapeutic strategies for
intestinal inflammation [92].
Pathogen-secreted QS signals may influence the mi-
gration and activation of intestinal DCs. Bacterial 3O-
C12-HSL and Pseudomonas quinolone signal (PQS) are
validated to participate in tuning DC programs to regu-
late T cell effector function, which acts by lowering IL-
12 production of DCs without altering their IL-10
release [93]. This suggests that 3O-C12- HSL and PQS
would drive the maturation pattern of stimulated DCs
awry from a pro-inflammatory T-helper type I (Th1)
response and thereby decreasing the antibacterial activity
of the adaptive immune defense. Thus 3O-C12-HSL and
PQS seem to possess dual activities during the process
of infection —— inducers of virulence factors, and
immune-modulators facilitating the persistent infection
of pathogen.
Certain infectious diseases have been demonstrated to
hinder the onset of autoimmune disorders as observed
with animal models, suggesting the probable impacts of
these infectious agents in pathology of mammalian
autoimmune diseases. Small molecules/proteins isolated
from the infectious agents have shown to account for
these protective effects [94]. Previous studies indicated
that P. aeruginosa QS signal OdDHL (viz. 3O-C12- HSL)
could delay the onset of type 1 diabetes (T1D) in the
non-obese diabetic (NOD) mouse model. Furthermore,
using an antigen-presenting cell-free system, the authors
showed that 3O-C12-HSL could not only inhibit the
proliferation of naïve T cells but directly suppress the
differentiation of T cell subsets; however, no effects was
seen with 3O-C12-HSL on the inhibition of primed and
committed differentiated T cell responses, suggesting
that 3O-C12-HSL-mediated immune mechanism may be
restricted to initial stages of infection [94].
Gut-residing nonpathogenic Escherichia coli may se-
crete QS signals including autoinducer 2 (AI-2). In view
of AI-2’s relevance as a bacterial signaling molecule, its
actions in HCT-8 cells (intestinal epithelial cells, IEC)
were recently investigated [95]. Inflammatory cytokine
IL-8, a key player in attracting neutrophils, was found to
be initially upregulated at all levels of AI-2 examined at
6 and 12 h post-treatment, followed by a distinct down-
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regulation at 24 h post-treatment. Collectively, non-
pathogenic bacterial QS signal AI-2, is likely an IEC
signaling molecule and may stimulate the transcription
of immune-associated pathways, followed by the upregu-
lation of negative-feedback elements that may block the
inflammatory responses.
Gut microbes may produce metabolites other than
SCFAs and QS signaling molecules, for instance, poly-γ-
glutamic acid (γ-PGA) during fermentation of soybeans.
Gamma-PGA is present predominantly in Bacillus subti-
lis but absent in mammals [96]. Studies have demon-
strated that Bacillus-originated γ-PGA can regulate Th1/
Th2 cell development depending on APC, specifically by
stimulating DCs to favor the polarization of naïve CD4+ T
cells toward Th1 rather than Th2 cells, and it also con-
trols Th17 cell development through APC-dependent
and -independent mechanisms [96].
There is evidence to show that Bacillus-derived γ-
PGA may signal naïve CD4+ T cells to promote se-
lective differentiation of Treg cells and to repress the
differentiation of Th17 cells [97]. The initiation of
FoxP3 expression by γ-PGA was partially attributed
to TGF-β induction via a TLR-4/myeloid differentiat-
ing factor 88 (MyD88)-dependent pathway; however,
this pathway was dispensable for γ-PGA suppression
of Th17 differentiation. Intriguingly, in-vivo sup-
plementation of γ-PGA was found to be able to
attenuate symptoms of experimental autoimmune en-
cephalomyelitis (EAE), concurrent with the declined
Th17 cell infiltrations in the central nervous system.
Therefore, γ-PGA was characterized as a type of the
microbe-associated molecular pattern (MAMP), and
also a novel mediator of autoimmune responses that
enables the selective differentiation of anti-inflammatory
Treg cells and dampens the differentiation of proin-
flammatory Th17 cells. The above finding is reminis-
cent of the previous demonstration in the murine
model that exposure to γ-PGA could suffice to allevi-
ate Th2-mediated allergic asthma, likely by activating
DCs to favor the induction of Th1 over Th2 cells
[98]. Altogether, these results may underpin the thera-
peutic potential of γ-PGA in the Th17-dominated
autoimmune disorders [97].
Commensals and gut homeostasis
Commensal-induced Tregs mediate immunopathology
Intestinal commensal microbiota have been shown to
modulate conventional T cell and Treg responses that
are required for effective host defense against pathogens
while circumventing autoimmune responses and other
immunopathologic consequences. The presence of Treg
cells can normally prevent inappropriate T cell responses
towards commensal bacteria that may otherwise lead to
inflammatory diseases.
Bifidobacterium infantis 35624 strain, originally iso-
lated from human gastrointestinal mucosa, has received
much attention in the past decade. Supplementation of
commensal B. infantis 35624 was reported to induce the
generation and function of Treg cells that control exces-
sive NF-κB activation in mice, thereby contributing to
host homeostasis maintenance and conferring protection
from improper activation of the innate immunity against
a translocating and spreading pathogen like Salmonella
typhimurium [99]. Further studies by the same group
demonstrated that administration of this commensal to
healthy human volunteers could result in the augmented
numbers of Foxp3 T cells and enhanced secretion of
peripheral blood mononuclear cell IL-10 [100]. It is
known that microbiota-DC interactions are able to in-
duce Treg cells. B. infantis-stimulated human DCs were
observed to induce Foxp3 and IL-10 secreting T cells
[100]. Generally speaking, DC subsets, referring to
monocyte-derived DCs (MDDCs), myeloid DCs (mDCs)
and plasmacytoid DCs (pDCs), use different pattern rec-
ognition receptors to coordinate the Treg cell induction,
Specifically, MDDC IL-10 and mDC IL-10 secretions
were relied on TLR-2 and retinoic acid, whereas IL-10
secretion by pDC was dependent on TLR-9 and required
indoleamine 2, 3-dioxygenase (IDO) [100].
Commensal microbiota have been validated to con-
tribute to the homeostatic proliferation of Foxp3− con-
ventional CD4+ T cells and Foxp3+ Tregs [101]. Under
long-term antibiotic administration, a manifest decline
of conventional CD4+ T cell proliferation was detected
in a systemic pattern whereas Foxp3+ Treg prolifera-
tion was observed to be locally distributed in gut-
draining mesenteric lymph nodes and Peyer’s patches.
Moreover, the proliferative response to microbial com-
ponents was not mediated by TLRs as various TLR-
and MyD88-deficient mice exhibited normal or even
elevated conventional T cell and Foxp3+ Treg prolifer-
ation. Taken together, commensal microbiota-derived
stimuli are able to promote the cycling of both con-
ventional CD4+ T and Foxp3+ Treg cells, irrespective
of TLR signaling.
An elaborately-designed study illustrated that a com-
plex mixture of 46 strains of Clostridium, in particular
Clostridium clusters IV and XIVa, could induce TGF-β
in intestinal epithelial cells to intensify the subsequent
accumulation of IL-10-producing induced T regulatory
(iTreg) cells, which were known to suppress colitis in a
DSS-challenged colitis model [72]. Certain Clostridium
species, rather than Lactobacillus or Bacteroides ones,
were found to suffice to increase the frequency of
Foxp3+ Treg cells in the colon when transferred into
germ-free (GF) mice. Consequently, oral administration of
Clostridium during the early life of conventionally-raised
mice might confer resistance to colitis and systemic IgE
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responses in adult mice, pinpointing a novel approach to
treating autoimmunity and allergy [72].
It is becoming evident that the diversity and compos-
ition of commensal microbiota in human intestines may
influence the equilibrium of conventional T and Treg
cells, thereby modulating host gut immunity.
Commensal bacteria and the barrier function of intestinal
epithelium
The mammalian digestive tract has evolved and devel-
oped a variety of attributes to defense against microbial
infection. A monolayer of columnar epithelial cells,
termed intestinal epithelial cells (IECs), connects each
other via tight junctions, and is known to line the small
and large intestines as well as the Peyer’s patch regions.
The tight junctions are thought to limit the diffusion of
moieties between epithelial cells [102]. IECs, as a barrier
between the intestinal lumen and host connective tissues,
are continuously subjected to numerous immunologic
stimuli [60]. Commensals are believed to promote the
generation and maturation of organized gut-associated
lymphoid tissues (GALTs) because they facilitate recruit-
ment of immune cells to the mucosa [14]. Evidence has
revealed that the GALTs and other lymphoid tissues are
poorly developed in GF mice, however, this deficiency
could be rectified by the inoculation of conventional flora
or oral supplementation of TLR ligands, which indicates
that: (1) signals/products derived from the commensals
play indispensable roles in the development of immune
tissues; (2) TLR signaling is essential for the maturation of
the developing immune system [103].
An aberrant epithelial barrier may primarily be in-
volved in chronic inflammatory disorders and even
cancers [104]. Impaired epithelial integrity is demon-
strated to activate the resident inflammatory cells in
response to pathogenic invaders or endogenous ligands,
which, coupled with a failure of normal regulatory
mechanisms that limit leukocyte activation, would initi-
ate a cascade leading to chronic inflammation [104]. In
addition, the integrity of the epithelial barrier relies on
homeostatic regulatory mechanisms involving mucosal
induction of Treg cells, where commensal-host interac-
tions undoubtedly play a role. Secretory IgA (SIgA) are
believed to orchestrate with innate defense components
for protecting the epithelium and strengthening its bar-
rier function [105]. Segmented filamentous bacteria
(SFB), a class of anaerobic and clostridia-related spore-
forming commensals present in the gut of mammals (i.e.
mice and humans), are found to be intimately attached
to the epithelial lining of the mammalian GI tract [106,
107], and to actively interact with immune system [107].
SFB inoculation into GF mice has been validated to
induce the production of SIgA and the recruitment of
intraepithelial lymphocytes (IEL) to the gut [73, 108].
Work with immunocompetent mice has delineated that,
intestinal SFB colonization is able to promote the pro-
duction of mucosal SIgA, the differentiation of effector
T helper 1 (Th1), effector T helper 2 (Th2) and Th17
cells, and the development of Treg cells [109]. Previous
experimental data revealed that IEL, particularly γδIEL,
might be involved in the regulation of the generation
and differentiation of IECs [110]. Collectively, SFB is
likely to closely participate in the regulation of IEC
proliferation, suggesting its contribution to the barrier
functionality of intestinal epithelium.
Another paradigm of gut commensal that affects gate-
keeper functionality of epithelia is believed to be Akker-
mansia muciniphila [111]. A. muciniphila possessing
mucin-degrading activity is a dominant human bacter-
ium colonizing in the mucus layer of gut. The presence
of A. muciniphila was demonstrated to be inversely
correlated with body weight in mice and humans [111].
Administration of A. muciniphila appears to elevate the
intestinal levels of endocannabinoids that controls in-
flammation, the gut barrier, and gut peptide secretion. A
hypothesis has been proposed that A. muciniphila may
play a crucial role in the mutualism between the gut
microbiota and host, which regulates gut barrier func-
tion and other physiological functions during obesity
and type 2 diabetes (T2D). Furthermore, merely viable
A. muciniphila is able to exert the above-described
actions because supplementation of heat-killed cells
failed to improve the metabolic profile or to enhance the
mucus layer thickness [111].
Commensal bacteria modulate gut homeostasis
Previous studies have revealed that Bacteroides thetaio-
taomicron, a dominant member of gut microflora in
mice and human, has potential of triggering the develop-
ment of intestinal submucosal capillary network [112].
Angiogenesis stimulation by B. thetaiotaomicron was
illustrated to be driven through bacteria-sensing Paneth
cells in the epithelial crypt. Paneth cells, a key compo-
nent of the intestinal innate immunity, are known to
secrete an arsenal of antimicrobial peptides and proteins
into the gut lumen [113]. Indigenous inhabitant B.
thetaiotaomicron is thus pinpointed to be involved in
both the mucosal barrier reinforcement and immune
modulation.
The colonization of SFB, as previously described in the
context of barrier functionality of intestinal epithelium,
may also direct post-natal maturation of the gut mucosal
lymphoid tissue, trigger a potent and broad IgA re-
sponse, stimulate the T-cell compartment, and upregu-
late intestinal innate defense mediators, suggesting
immune-stimulatory capacities of SFB [114, 115]. Apart
from their abilities to educate the gut immune system, it
becomes evident that SFB colonization may act as an
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adjuvant on systemic responses and thereby exacerbating
pathologies in the murine models of encephalitis and arth-
ritis, while conferring the genetically-predisposed mice
protection from the development of T1D [98, 116–118].
SFB are thought to be species between obligate and facul-
tative symbionts due to their high auxotrophic demands
as evidenced by genomic sequencing of these symbionts
with the rodents. These findings collectively suggest that
SFB may benefit, at least nutritionally, from their inter-
action with the host and have thus evolved adaptive strat-
egies to cope with host immune responses for maintaining
their intestinal niches [119–121]. By using SFB-host cell
co-cultivation system, Schnupf and co-workers [107]
unraveled that single-celled SFB isolated from monocolo-
nized mice underwent morphologic development and
differentiation to release viable infectious particles,
termed the intracellular off-springs, which enabled
their colonization within the host for the induction of
signature immune responses. In-vitro studies further
demonstrated that those intracellular off-springs pos-
sessed the capabilities of attaching to host cells and of
recruiting actin. Moreover, the up-regulations of host
innate defense genes, inflammatory cytokines, and chemo-
kines were found to be elicited by SFB [107].
New studies by Littman group [122] reported that,
after inoculation of SFB, differentiation of Th17 cells
was induced during which the IL-22 production by type
3 innate lymphoid cells (ILC3) was required for potenti-
ating epithelial secretion of serum amyloid A (SAA).
Moreover, while “poised-state” T cells expressing the
Th17 main regulator RORγt (RORγt + Th17) were dis-
tributed throughout the gut, IL-17-expressing Th17 cells
were limited to the small intestine ileum, coincided with
the site of SFB adhering to epithelium. Another inde-
pendent work by Atarashi et. al. illustrated that this pref-
erential induction of IL-17 in Th17 cells might be
attributed to intimate SFB attachment to the small intes-
tine epithelium [123]. Overall, these recent findings have
revealed a novel circuit of epithelial cell perception of
intestinal commensals like SFB, the latter of which could
modulate host immune responses including cytokine
production, thereby facilitating our further exploitation
of roles of Th17 cells in the regulation of mucosal
defenses and control of autoimmune diseases.
Microbiota, by establishing inter-connected metabolic/
nutritional networks and developing biofilms among
their components, are able to confine the resources to
potential pathogens that out-compete well-adapted indi-
genous microbes for ecological niches [124]. In addition
to the occupation of ecological niches by commensals,
documented are other mechanisms such as homeostasis-
maintenance of commensals towards host. Studies have
demonstrated the capabilities of non-virulent bacteria
Lactobacillus spp., Bacteroides spp., and Escherichia coli
to suppress poly-ubiquitylation and subsequently de-
grade IκB–α, which in turn inhibits the NF-κB activation
and thereby leading to immune hypo-responsiveness in
the intestines [125]. Supporting this finding, B. thetaio-
taomicron was validated to stimulate the export of RelA
(p65 subunit of NF-κB) from the host nucleus, which
lowered the transcription of NF-κB-dependent genes
[126]. Moreover, Lactobacillus casei was shown to exert
anti-inflammatory actions through repressing the deg-
radation of the inhibitor of NF-κB (IκB) as well [127].
Subsequent studies with L. casei DG (a probiotic strain)
revealed that rectal administration of L. casei DG
coupled with 5-aminosalicylic acid (5-ASA), rather than
5-ASA in combination with oral administration of this
probiotic strain, could alter colonic microbiota compos-
ition by increasing Lactobacillus spp. and declining
Enterobacteriaceae. In addition, this approach remark-
ably reduced the levels of TLR-4 and IL-1β mRNA while
increasing mucosal IL-10. Accordingly, modification of
mucosal microbiota by L. casei DG and its impacts on the
mucosal immunity seem to be critical for the favorable
roles of this probiotics in ulcerative colitis patients [128].
Another independent study presents the induction of
host Treg cells and mucosal tolerance by Bacteroides
fragilis capsular polysaccharide (PSA) [129]. The under-
lying mechanism may be related to the perception of B.
fragilis-released PSA by host DCs through TLR2, which
results in elevated production of Treg cells and anti-
inflammatory cytokines and thereby contributing to col-
itis alleviation [129]. The finding of outer membrane
vesicles (OMVs)-associated PSA not only reveals immu-
nomodulatory effects of B. fragilis but also represents a
novel mechanism regarding inter-kingdom cross-talk
between the commensal and mammalian cells mediated
by a bacterial molecule.
It is believable that more and more immunomodualtory
commensals will be unveiled owing to the advances in our
research techniques such as gnotobiotic cultivation, com-
parative metagenomics/meta-proteomics approach, deep
sequencing, microbiome studies, metabolomics related
systems biology studies, in-situ 3D imaging, molecularly
biological and immunologic methods, thereby deepening
our understandings of the mechanisms underlying the
interaction of commensal-host immune system. In addition
to the documented effects of commensals on gut homeo-
stasis (Fig. 2), the anticipated findings of commensals, most
of which may fall into unculturable clades, would shed light
on our novel therapeutic regimen to treat autoimmune
disorders and inflammation associated with dysbiosis in
human intestine.
Inter-species signals among commensals in the gut
An equilibrium among the gut, its beneficial microbiota
(commensals) and pathogens is vital for human health,
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which represents an outcome of intricate and finely-
tuned communication between microbes and host as
well as that of cross-talk among microbes. Indole,
present at high amounts (250–1100 μM) in the gut,
probably serves as an inter-kingdom signal during the
interactions of commensals and host intestinal cells [78].
Previous work demonstrated that indole, secreted by
commensal E. coli, could lower the chemotaxis, motility,
and adherence of pathogenic E. coli to host intestinal epi-
thelial cells [130]. Furthermore, exposure to physiologic-
ally relevant levels of indole was found to up-regulate the
genes associated with the mucosal barrier reinforcement
and mucin production, which was in line with an elevation
in the trans-epithelial resistance of the human enterocyte
HCT-8 cells. In addition, indole was validated to
decline the indicators of inflammation, such as the
TNF-α-mediated NF-κB activation, the expression of
proinflammatory IL-8, and to attenuate the attachment of
pathogenic E. coli to HCT-8 cells; conversely, it could
elevate the expression of anti-inflammatory IL-10. Analo-
gous to the observations with probiotics strains, this study
strongly suggested that commensal-secreted indole could
serve as a beneficial signaling molecule for intestinal epi-
thelial cells and thus be crucial in the protective responses
to gut pathogens [130].
An independent investigation with a murine model
has revealed the association between commensal-derived
indole and enhanced epithelial barrier function. GF mice
exhibited a reduced expression of junctional complex
molecules in colonic ECs. Oral administration of indole-
containing capsules was observed to cause an elevated
expression of both tight junction (TJ)- and adherens
junction (AJ)-associated molecules in colonic ECs of GF
mice. In accordance with the increased expression of
these junctional complex molecules, GF mice treated
with indole were found to display an enhanced resist-
ance against DSS-induced colitis. Protective potential of
indole from DSS-induced epithelial insults was found in
the GF mice as well as in the specific pathogen-free
(SPF) mice. Altogether, the findings suggest the involve-
ment of gut commensal-derived indole in the epithelial
barrier enhancement in the colon [131].
There is evidence to reveal that glucagon-like peptide-
1 (GLP-1) secretion from murine enteroendocrine cells
is modified by the exposure of indole at similar level to
that detected in the human large intestine [132].
Strikingly, indole was observed to elevate the release of
GLP-1 during short exposure time but mitigate GLP-1
secretion over longer time. The dual effects of indole
were thought to involve two key molecular mechanisms
in intestinal enteroendocrine L cells. Indole, on the one
hand, could suppress voltage-gated K+ channel, elevate
the temporal width of action potentials provoked by L
cells, and result in the increased Ca2+ entry, thereby
triggering abrupt GLP-1 secretion. On the other hand,
indole could reduce ATP production by blockage of
NADH dehydrogenase and thus leading to a lasting
decline of GLP-1 secretion. Accordingly gut microbiota-
originated indole is regarded to have a remarkable effect
on host metabolism, underpinning indole as a signaling
molecule that mediates the communication of gut
microbiota with enteroendocrine L cells [132].
Indole is widely recognized to regulate versatile as-
pects of indole-producing bacteria, such as spore forma-
tion [133], plasmid stability [134], drug resistance [135],
biofilm formation [136, 137], and virulence [138].
Fig. 2 Commensals and gut homeostasis. *Segmented filamentous bacteria (SFB) also possess immunostimulatory effects, including induction of
SIgA response, post-natal maturation of gut-associated lymphoid tissue (GALT), and stimulation of T cell compartment. IE: intestinal epithelium
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Interestingly, besides indole-producers, indole also influ-
ences several physiological traits in non-indole-producing
bacteria. For instance, Salmonella enterica serovar Typhi-
murium, a gut pathogen unable to produce indole, relies
on indole in its drug resistance and virulence as evidenced
by the down-regulations of host cell invasion-related
genes, and of bacterial flagellum production upon indole
exposure [139]. Indole, present in the gut commensal con-
sortium, has been validated to be a key signaling molecule
for inter-species communication to control drug resist-
ance and virulence of S. enterica, a causal agent for human
gastroenteritis, bacteremia, and typhoid fever [140].
A delicately-designed study was conducted regarding
population dynamics during the development of antibiotic-
resistant E. coli strains [141]. A continuous culture of E. coli
was performed under the exposure to increased levels of
antibiotic. Less resistance was observed for a large majority
of the above isolates than the overall E. coli population.
There was evidence to reveal that few highly-resistant mu-
tants could enhance the survival of the less-resistant E. coli
cells within the same population, partially by indole, which
is a bacterial signal produced by unstressed and robustly-
growing E. coli cells. Indole was known to transcriptionally
activate drug efflux pumps and to trigger protective mecha-
nisms under oxidative stress. Within the population,
synthesis of indole might come at a fitness cost to the
highly-resistant bacterial isolates, which is achieved by
drug-resistance mutations irrelevant to indole synthesis as
determined by whole-genome sequencing. Accordingly this
work underpins that a population-based resistance mech-
anism may constitute a form of kin selection by which a
minority of resistant mutants can, at certain cost, endow
protection to other more susceptible cells and thereby
promoting the survival of the entire population under
unfavorable conditions including antibiotics stress [141].
Besides indole itself, its derivative indole-3-acetonitrile
(IAN) has also been shown to affect the virulence of
opportunistic pathogen C. albicans by attenuating the
fungal attachment to HT-29 intestinal epithelial cells,
and by inhibiting fungal filamentation and biofilm
formation [142]. Moreover, indole and IAN could
specifically stimulate the transcription of NRG1, the
transcriptional repressor that influences C. albicans
pathogenesis. The work further adopted the model host
Caenorhabditis elegans to in-vivo illustrate that the
exposure to indole or IAN could suppress fungal in-
fection and reduce C. albicans colonization in the
nematode gut. This was in line with a previous demon-
stration that extracellular indole was able to activate
genes in association with Vibrio polysaccharide (VPS)
production, as well as to influence the expression of
various bacterial genes relative to virulence, transport,
iron utilization and motility, indicative of indole as a
signal in Vibrio [143].
More recently, indole 3-propionic acid (IPA), another
derivative of indole, is reported to cause the down-
regulation of TNF-α in enterocytes and the up-regulation
of junctional protein-coding mRNAs while acting as an
in-vivo ligand for pregnane X receptor (PXR), the xeno-
biotic sensor [144]. PXR has previously been characterized
to be a mediator in microbial indole-dependent regulation
of host intestinal barrier function [144]. In their work,
manifestly leaky intestinal epithelia were observed concur-
rent with the up-regulated TLR signaling pathway in PXR
deficient (Nr1i2 −/−) mice. Furthermore, the above-
mentioned epithelial barrier leakage was abolished in
Nr1i2−/− Tlr4−/− mice. Therefore a direct chemical com-
munication has been proposed between the intestinal
symbionts and PXR to regulate mucosal integrity through
an indole signaling pathway in intestines [144]. Indole is
widely accepted as a key player in ecological balance,
bacterial physiology, and possibly human health [145].
Overall, evidence to date suggests a rational that indole
and indole-related signaling molecules may be indispens-
able in the inter-kingdom regulatory networks pertinent
to intestinal health.
Microbiota and metabolic disorders
From the metabolic viewpoint, gut microbiota may be
recognized as a consortium capable of modulating host
physiology and immunity [146]. Gut microbes impact
local and systemic inflammation through pattern recogni-
tion receptors (PRRs) [147, 148]. Accumulating evidence
has revealed that gut microbes may regulate fat mass
expansion via their fermentative products and mediate
the suppression of the fasting induced adipose factor
[69, 149–152]. Intestinal dysbiosis, referring to “alter-
ations in the composition and abundance of the gut
microbiota as compared to healthy individuals” [153], is
believed to account for inflammatory, metabolic diseases
and even dysfunctions of central nervous system (Fig. 3).
Diabetes and obesity
It is thought that commensals are able to exert crucially
biological actions on their host tissues, ranging from meta-
bolic regulations to immune-modulations. Any unequili-
brium between the host and commensals would lead to the
passage of the luminal contents into the underlying tissues
and thus into the bloodstream, triggering the immune
response activation and the ensuing gut inflammation,
which may contribute to various diseases including infec-
tious enterocolitis, IBD, obesity, diabetes, irritable bowel
syndrome, small intestinal bacterial overgrowth, hepatic
fibrosis, food intolerances and atopic manifestations [154].
T1D and autoimmunity Data heretofore underpin the
evolving theory that gut microbiota serve as an organ with
a myriad of previously neglected or poorly-understood
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metabolic, immunologic, and endocrine-like effects on
human health [155]. An evident correlation has been
validated between the altered intestinal microbiota com-
position with the onset of autoimmune disorders such as
T1D [156]. Gut microbiota is found to participate in the
progression of early incidence of T1D, which is originated
from T-cell-mediated destruction of insulin-producing
pancreatic β-cells. Experimental data suggest that dialogue
between gut microbiota and host innate immunity is
closely associated with islet destruction [156, 157]. Con-
sequently, the gut microbiota-innate immunity axis is
proposed to be crucial in the development of T1D.
Accumulating evidence from human and animal models
suggests environmental cues (including the human micro-
bial milieu) may be indispensable in T1D etiology [158].
The substantially rising incidence of T1D in recent
decades is found in very young children worldwide,
particularly in the developed countries. Children who
progressed to T1D had decreased richness of Firmicutes
and increased Bacteroidetes over time whereas the situ-
ation is the opposite for age-matched healthy children
(with increased Firmicutes and decreased Bacteroidetes).
In contrast to children with ongoing autoimmunity,
healthy children harbored a more diverse and stable intes-
tinal microbiome [157]. Studies with non-obese diabetic
(NOD) mice have shown that their incidence of spontan-
eous T1D could be affected by the microbial milieu in the
animal housing facility or by exposure to microbial stimuli
such as administration with mycobacteria or various
microbial products [158, 159].
The infant gut exhibits a Th2-skewed cytokine profil-
ing that favors triggering immunological ignorance
toward bacterial and dietary components [160]. Hansen
et al. [160] tested the impacts of vancomycin (an anti-
biotic that inhibits biosynthesis of G+ bacterial cell wall)
on the early microbial colonization of the gut by admin-
istrating the drug at neonatal stage of mice. Results
showed that vancomycin depleted many major genera of
G+ and G− bacteria whereas one species, Akkermansia
muciniphila, was not affected rather became dominant.
Furthermore, overall diabetes incidence was found to be
evidently lower in the neonatally vancomycin-treated
mice than untreated controls, whereas the blood glucose
levels significantly lower in the mice treated as adults than
the other groups. In addition, an increase in cluster of
differentiation CD4+ T cells producing pro-inflammatory
cytokines was observed in the neonatally vancomycin-
treated mice. Taken together, it is suggested that the early
postnatal period would be critical for microbial protection
from T1D, and A. muciniphila is considered to be a bene-
ficial bacterium to protect the host from T1D onset,
particularly at infancy [160].
MyD88 protein, an adaptor for multiple innate im-
mune receptors that recognize microbial stimuli, is
widely accepted to be one of the major signaling mole-
cules participating in the activation of TLR (except
TLR3) [161]. Studies have indicated that no T1D onset
is observed in specific SPF NOD mice devoid of MyD88
protein [158]. The manifestation could be attributed to
commensal microbiota because: (1) GF MyD88-deficient
Fig. 3 Effects of gut microbiota on the peripheral tissues beyond the gut. CNS: central nervous system
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NOD mice developed distinct diabetes; (2) T1D was mit-
igated after colonization of these GF MyD88-deficient
NOD mice with a defined bacterial phylum of healthy
gut. The authors also illustrated that depletion of
MyD88 could lead to alteration in the composition of
the distal gut microbiota, and that exposure to the
microbiota of SPF MyD88-deficient NOD donors might
alleviate T1D in GF NOD recipients. Consequently,
interaction of the intestinal microbiota with the innate
immunity may be a key player in the epigenetic modula-
tion of T1D susceptibility [158].
There is a long-time plausible theory termed hygiene
hypothesis, meaning that a decline of early childhood
exposure to microbes (both pathogenic and symbiotic)
increases the susceptibility of autoimmune disorders by
suppressing natural development of immune system,
resulting in defective Treg cell induction and the ensuing
loss of self-tolerance. This hypothesis has evolved and
led to the rational that gut microbiotal alteration could
be one of predisposing factors for the onset and develop-
ment of autoimmunity such as T1D.
Recent work by Toivonen et al. [162] revealed the
association of fermentable fibers (FF) with risk of T1D
development using NOD mice. Their results showed
that NOD mice fed with FF-free semisynthetic diets
were distinctly protected from diabetes, whereas the FF-
rich semisynthetic diet-fed counterparts displayed in-
creased incidence of T1D. This manifestation was found
to be correlated to the alterations in gut microbiota
composition as evidenced by more dominating Bacteroi-
detes and reduced Firmicutes at phylum level in NOD
mice supplied by FF-rich meal than those by FF-free
meal. The high diabetogenic potential of FF, in particular
of pectin and xylan, was linked to colonic expression of
proinflammatory and stress-associated genes [162]. This
taxonomic shift in gut microbiota associated with high
risk of T1D incidence, Bacteroidetes dominating at
phylum level compared to Firmicutes, is reminiscent of
the documented features in individuals with Crohn’s
disease [163], which is one of autoimmune disorder in
human GI tract. Another study proposed that the char-
acteristic manifestation of T1D —high Bacteroidetes to
Firmicutes ratio, a lack of butyrate-producing bac-
teria, reduced bacterial diversity and weak community
stability— occurred after the appearance of autoanti-
bodies, suggesting the possible involvement of in-
testinal microbiota in the progression from pancreatic
β-cell autoimmunity to clinical disorder but not in
the onset of disease process [164].
Although the exact mechanism about local tolerance in-
duction by the microbiota remains elusive, the finding that
the normal intestinal microbiota could attenuate the pro-
gression of autoimmune T1D in a MyD88-independent
manner would provide a different viewpoint into disease
etiology. Rational utilization of live microbial strains or
microbial products thereof may represent new therapeutic
promises for T1D [157]. Continued endeavor to define the
specific role of intestinal microbiome (the collective ge-
nomes of microbiota) in the onset of T1D is urgently
needed for the design and development of novel disease
preventative or therapeutic regimen.
T2D and obesity Apart from T1D, extensive studies
show that the intestine microbes affect host energy har-
vest in mammals, suggesting a link of gut microbiota with
obesity [155]. Firmicutes, Bacteroidetes, Actinobacteria
and Proteobacteria are known to dominate the human
intestinal microbiota of adults [155]. It is well accepted
that host body habitus is relevant to the composition of
the gut microbiota. Ley et al have analyzed the micro-
biome of lean (ob/+ or +/+) mice in comparison to that of
their obese (ob/ob) siblings which are homozygous for a
mutation in the leptin gene with the resultant phenotype
of severe obesity [158]. Analogous to human, Firmicutes
and Bacteroidetes are predominant bacterial phyla in
healthy murine intestines. The ob/ob mice are character-
ized by an increased prevalence of Firmicutes and a re-
duced abundance of Bacteroidetes as compared to lean
sibling mice. Additionally, the microbiome of obese mice
appears to be more efficient in energy harvest, as evi-
denced by the lower amount of energy remaining in the
feces of obese mice than that in lean controls [152].
A pioneering work demonstrates the association of
type 2 diabetes (T2D) with the translocation of com-
mensal bacteria [161]. The authors presented that, dur-
ing the early onset of high-fat diet(HFD)-induced
diabetes, live commensal intestinal bacteria were actively
translocated through intestinal mucosa into blood and
the mesenteric adipose tissue (MAT) where they trig-
gered a low-degree bacteremia [161]. The translocation
relied on the microbial PRRs CD14 and Nod1 because
no translocation was observed in mice devoid of CD14
or Nod1; however, it was elevated in Myd88-deficient and
ob/ob mice. This metabolic bacteremia was definitive of
an augmented co-localization with DCs from the intes-
tinal lamina propria and of an elevated intestinal mucosal
adherence of non-pathogenic E. coli. In addition, this
manifestation could be rectified by 6-week probiotics
administration with Bifidobacterium animalis subsp. lactis
420, a strain known to promote the mammalian inflam-
matory and metabolic status. This work proposed, for the
first time, a new therapeutic regimen for the metabolic
disease — intestinal bacterial adherence, bacterial trans-
location, or receptors of bacterial fragments could be
promising targets to preventing/or inverting the incidence
of diabetes and obesity [161]. This finding also broadens
the avenue for treatment of metabolic disorders using
probiotics strategies.
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Liver diseases
Extensive studies with animal models have indicated
that: (1) progression of chronic liver diseases like liver fi-
brosis relies on gut bacteria-derived products [165, 166],
which may be attributed to the increased intestinal per-
meability; (2) bacterial translocation is a crucial player in
fibrosis progression during the development of chronic
liver disorders [167]. However, the precise mechanisms
underlying the mucosal barrier breach or bacterial trans-
location remain elusive. The microbiota is believed to be
required for liver homeostasis in chronic liver injury
[167]. A low baseline level of bacterial products is postu-
lated to enable hepatic protection from toxic factors as
supported by: (1) the down-regulation of hepatic expres-
sion of P450 enzymes (i.e. Cyp26a1) in the GF mice after
chronic liver injury; (2) more vulnerability of hepatocytes
to toxin-induced cell death in Myd88/Trif-deficient mice
devoid of downstream TLR signaling than wild-type con-
trols. Notably, higher systemic levels of microbial products
are unable to provide additional resistance, but activate
hepatic stellate cells and Kupffer cells/recruited macro-
phages to exacerbate liver damage. Furthermore, microbial-
derived indole-3-propionic acid (IPA) might confer
hepatic protection from oxidative stress. Altogether,
the commensal microbiota endows prevention against
fibrosis upon chronic liver injury in mice, representing a
novel potential therapeutic regimen for liver diseases.
An elaborately-designed study has delineated the link
between inflammasome-mediated dysbiosis and progres-
sion of non-alcoholic fatty liver disease (NAFLD) [168].
NAFLD is a prevalent chronic liver disorder in the de-
veloped countries, 20% of which may be proceeded to
chronic hepatic inflammation (non-alcoholic steatohepa-
titis, NASH), the latter being associated with cirrhosis,
portal hypertension and hepatocellular carcinoma. How-
ever the precise mechanism underlying the progression
from NAFLD to NASH remains to be elucidated.
Henao-Mejia and colleagues have demonstrated that the
NLRP6 and NLRP3 inflammasomes and their effector
IL-18 can negatively regulate NAFLD/NASH progres-
sion as well as multiple aspects of metabolic syndrome
by modulating the gut microbiota [168]. Alterations in
the gut microbiota configuration in mice are observed
under deficiency of inflammasomes, which links to exac-
erbated hepatic steatosis and inflammation via influx of
TLR4 and TLR9 agonists into the portal circulation,
resulting in the enhanced hepatic TNF-α expression that
promotes NASH progression. Moreover, exacerbation of
hepatic steatosis and obesity were observed while
inflammasome-lacking mice were co-housed with wild-
type controls. Taken together, changes in the gut
microbiota-host interaction derived from the impairment
in NLRP3 and NLRP6 inflammasome sensing, may govern
the propensity for development of multiple metabolic
syndrome-associated abnormalities such as NAFLD-
NASH progression [168]. The above findings would shed
light on the crucial role of the microbiota in the pathogen-
esis of systemic auto-inflammatory and metabolic disor-
ders that are seemingly irrelevant. Analogous to metabolic
disorders (i.e. obesity), an increased prevalence of the
Phylum Firmicutes is definitive of gut dysbiosis following
the onset of toxic liver diseases including liver fibrosis and
NASH [168, 169], which underpins the involvement of
gut microbiota in the metabolic and immunologic aspects
of human health.
Inflammation tones
The functional links between gut microbiota and inflam-
mation/metabolic diseases have recently been illustrated
[170, 171]. Peroxisome proliferator-activated receptor γ
(PPARγ) is a well-recognized transcription factor to link
metabolism to inflammation in the intestine. In addition
to the GI tract, PPARγ is predominantly expressed in
adipose tissue and thus participating in the metabolic
regulation of lipids, glucose homeostasis, cell prolifera-
tion and differentiation as well as local inflammation. In
this regard, it is not surprising that microbiota-induced
PPARγ is able to exert various actions beyond the gut, as
evidenced by its regulatory effects on the expression of
Angiopoietin like protein-4 (Angptl 4), the latter of
which is responsible for lipid storage in the adipose
tissues [149, 172, 173]. Streptococcus salivarius, one of
the primo-colonizers of human oral and gut mucosal
surfaces, had previously been shown to influence inflam-
mation by down-regulating NF-κB in the intestinal cells
[174], and has recently been revealed to inhibit tran-
scriptional activity of PPARγ [172]. Upon exposure to S.
salivarius supernatant, the expression levels of I-FABP
(intestinal fatty acid binding protein) and Angptl 4 were
found to markedly drop among PPARγ-induced meta-
bolic genes in the IECs [172]. Altogether, data strongly
suggest that S. salivarius could exert dual effects on both
host inflammatory regulation and metabolism processes.
This is reminiscent of the past demonstration regarding
PPARγ-dependent anti-inflammatory mechanism induced
by nonpathogenic B. thetaiotaomicron that selectively
antagonizes NF-κB. It appeared that B. thetaiotaomicron
might target NF-κB subunit RelA by enhancing its nuclear
export through a mechanism independent of nuclear
export receptor Crm-1. PPARγ, together with nuclear
RelA, underwent nucleocytoplasmic redistribution upon
exposure to B. thetaiotaomicron [126]. A decline in
PPARγ is able to abrogate both the nuclear export of RelA
and anti-inflammatory effect of B. thetaiotaomicron [126].
Of particular interest, an ameliorating role of the gut
microbiota has been demonstrated with BaF3 mice, a mur-
ine leukemia model established by transplantation of BaF3
cells containing ectopic expression of Bcr-Abl oncogene
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and characteristic of cachectic symptoms such as loss of fat
mass, muscle atrophy, anorexia and inflammation at the
final stage [70]. The gut microbial 16S rDNA analysis
unraveled a dysbiosis and selective modulation of Lactoba-
cillus spp. (decline of L. reuteri and L. johnsonii/gasseri in
favor of L. murinus/animalis) in the BaF3 mice as com-
pared to controls. Restoration of Lactobacillus spp. by oral
administration with L. reuteri 100-23 and L. gasseri 311476
was found to decrease the expression of atrophy markers
(Atrogin-1, MuRF1, LC3, Cathepsin L) in the gastrocne-
mius and in the tibialis, a manifestation correlated with a
drop of inflammatory cytokines (IL-6, monocyte chemo-
attractant protein-1, IL-4, granulocyte colony-stimulating
factor). These beneficial effects are thought to be strain-
and/or species-specific since no impacts on muscle
atrophy markers and systemic inflammation were seen
with L. acidophilus NCFM administration under study
[70]. The aforementioned work collectively suggests
the gut microbiota as a promising therapeutic target
in the control of leukemia-associated inflammation
and relevant disorders in the muscle.
Central nervous system (CNS) and gut microbiome
A growing body of evidence has indicated that alter-
ations of the gut microbiome may result in dysregulation
of immune responses in both the gut and the distal
effector immune sites including the central nervous
system (CNS). Recent studies in experimental auto-
immune encephalomyelitis (EAE) — an animal model of
human multiple sclerosis, have revealed that modifying
certain intestinal bacterial populations may cause a pro-
inflammatory manifestation that in turn contributes to
the onset and development of autoimmune diseases, for
example, human multiple sclerosis. Conversely, some
commensal bacteria and their antigenic products, while
presented in the correct context, can protect against
inflammation within the CNS [175].
The mechanism governing this bi-directional commu-
nication between CNS and gut microbiome is postulated
to be related to microbial endocrinology—the ability of
bacteria to respond to as well as to produce the same
neurochemicals acting as neurohormones in the host
[176]. The field of microbial endocrinology was estab-
lished several decades ago when the term was initially
coined by Lyte [177, 178].
The ability of microbiota to produce neurochemicals
with hormonal activities suggests that influences of
microbiome interacting with host may not merely be
confined to the intestines, rather go beyond the gut.
Studies with GF animals and animals receiving patho-
genic challenges, probiotic strains or antibiotic medica-
tions, have unveiled important roles of gut microbiota in
the modulation of anxiety, depression, cognition and
pain [176, 179–182].
In human subjects with irritable bowel syndrome
(IBS), which are characteristic of altered microbial com-
position and diversity as compared to healthy controls,
emotional dysfunctions were found including anxiety
and depression [183]. An augmentation in the nerve-to-
mast cell proximity in the colonic mucosa of IBS
patients has been demonstrated to be correlated with
the severity and frequency of abdominal pain [179].
Cryan and colleagues [180] have shown that Lactoba-
cillus rhamnosus, a probiotic lactic acid bacterium, could
pose direct effects on murine emotional behaviors like
anxiety and depression, probably by mediating neuro-
transmitter (GABA) receptors [180]. Moreover, the
neurophysiological effects of L. rhamnosus were abol-
ished in the vagotomized mice, indicating the vagal
signaling as a predominant constitutive communication
pathway for modulating the bacteria-brain interplay.
Dietary alterations such as feeding of meat, which could
substantially vibrate the composition of the microbiome,
have been illustrated to promote memory and learning
in mice [181].
In addition to bacterial biosynthesis and sensing of
similar neurohormones found in the mammals, it is
postulated that the bacterial symbiosis with the intes-
tine plays a predominant role in the postnatal deve-
lopment and maturation of the host immune and
endocrine system, which underpins CNS function
[182]. Recent studies have demonstrated that host
microbiota controls maturation and function of micro-
glia in the CNS [184]. Microglia, as the tissue macro-
phages of the brain, are crucial for maintaining tissue
homeostasis, for scavenging dying cells/components,
and for eradicating pathogens through microbial
associated molecular pattern receptor-dependent and
-independent mechanisms [185]. Apart from their
aforementioned functions, microglia are central to
axon pruning and remodeling during development and
adulthood, indicating them as an essential player in
brain development [186].
Host microbiota are manifestly associated with micro-
glia homeostasis, as supported by the GF mice displaying
global defects in microglia with altered cell percentages
and an immature phenotype which leads to impaired in-
nate immune responses. Limited microbiota complexity
or temporal depletion of microbiota might contribute to
defective microglia in mice. Reintroduction of a complex
microbiota into the murine host could, to some degree,
rectify microglia properties [184]. Furthermore, SCFAs,
a category of gut microbiotal products as described earl-
ier in this review, were found to be able to modulate
microglia homeostasis [184]. Thus it is not surprising
that mice lacking the SCFA receptor FFAR2 would
mimic the impaired microglia as previously observed in
GF mice [184].
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Impaired immune system impacts intestinal microbiota
composition
The mucosal immune system –— constituting adaptive,
innate immune cells and the epithelium –— is consider-
ably affected by its microbial milieu [187]. There is accu-
mulating evidence to reveal vice versa, that the impaired
immune system influences the intestinal microbiota
composition and in turn links to diseases.
Disruption of innate immune pathways is able to cause
alterations in intestinal microbiota. For instance, Nod2,
a kind of PRRs in response to bacterial muramyl dipep-
tide, is associated with susceptibility to Crohn’s disease.
Analysis of intestinal bacteria from the terminal ilea of
Nod2-lacking mice demonstrated an increased load of
commensal resident bacteria. Furthermore, Nod2-deficient
mice abolished the capability of preventing pathogenic bac-
terial colonization from intestine [188]. Another independ-
ent study showed that Nod2 could profoundly influence
the early development and composition of the intestinal
microbiota [189]. Apart from Nods, TLRs — an essential
part of innate immunity — may influence intestinal mi-
crobiota as well. TLR5, expressed in the gut mucosa, is
recognized to participate in the defense against pathogens.
Recent experimentation with TLR5-lacking mice has
revealed dysbiosis (with over-numbered E. coli) and the
ensuing chronic inflammation, which in turn leads to
manifestation of metabolic syndrome [187, 190].
Investigation with MyD88−/− NOD mice also sup-
ports the aforementioned rational that impaired immune
system affects the intestinal microbiota composition.
MyD88−/− NOD mice possessed high abundance of
Bacteroidetes, and thereby circumventing the host
from T1D development [158]. Furthermore, more SFB
were observed in the small intestines of MyD88−/− mice
than wild-type counterparts [191], suggesting that the
depletion of MyD88 signals could alter the intestinal
microbiota composition.
Recent studies have shown that Crohn’s disease (CD)
patients with impaired immune system displayed a de-
clined biodiversity and prevalence of intestinal bacteria.
Particularly, an elevated risk of post-surgery CD recur-
rence is linked up with a decreased abundance of Faeca-
libacterium prausnitzii on resected ileal Crohn mucosa
[192]. F. prausnitzii, a prominent member of Firmicutes
and absent in CD patients’ microbiota, was demon-
strated to have anti-inflammatory effects in vitro and in
vivo. In Caco-2 cells, F. prausnitzii’s released metabolites
other than butyrate, could hamper the activation of NF-
κB and secretion of IL-8. Furthermore, in peripheral
blood mononuclear cells (PBMCs), F. prausnitzii was
able to induce a declined release of proinflammatory
cytokines IL-12 and IFN-γ, and an increased secretion of
anti-inflammatory cytokine IL-10. The spectrum of cyto-
kines secreted by PBMCs has been documented as an
indicator to assess the in-vitro and in-vivo immunomod-
ulatory potential of various bacterial strains [193].
Therefore F. prausnitzii could drive the immune re-
sponses toward Th2 pathway. F. prausnitzii displayed a
greater IL10/IL12 ratio than L. salivarius Ls33, a known
anti-inflammatory probiotic strain, indicating F. praus-
nitzii as a more potent probiotic species. Its in-vitro
effects were confirmed in vivo on TNBS-induced colitis
murine model. The aforementioned data collectively
showed that the dysbiosis associated with TNBS-
induced colitis (concurrent with impaired immune
system) was partially rectified by F. prausnitzii or its
supernatant [192].
Acquired immune deficits could affect the microbiota
composition as exemplified by patients with human
immunodeficiency virus (HIV) infection. Transmission,
propagation and persistence of HIV are thought to occur
largely in the host mucosal tissues [194]. Rapid depletion of
mucosal memory CD4+ T cells is observed during acute
infection and is sustained throughout the chronic phase of
disease, concurrent with a decline in the Th17/Tregs ratio,
an increase in CD8+ T cells, and a drop in the NK cells.
Moreover, HIV-infected subjects have elevated epithelial
permeability, systemic microbial translocation, and in-
creased serum inflammatory status, which are considered
to propel the disease progression to AIDS [195, 196]. Re-
cent studies have assessed the mucosal and fecal micro-
biome of treated HIV patients as compared to untreated
ones, which substantiates the altered microbial flora in HIV
patients [196–198]. The work by McCune’s group has in-
vestigated colonic microbiota composition of untreated
viremic HIV-infected subjects in comparison to that of un-
infected healthy controls [196]. It revealed that in HIV-
infected individuals, Erysipelotrichaceae family was the
most abundant, and Enterobacteriaceae the second most
abundant including species of Salmonella, Escherichia,
Serratia, Shigella and Klebsiella genera that are recognized
proinflammatory pathobionts. In contrast, distinctly re-
duced abundance of genera of Bacteroides and Alistipes
was found in HIV-infected subjects compared to healthy
controls [196]. Another study with rectal mucosal micro-
biota reported the compositional shifts in association with
HIV infection [198]. Relative abundance of Fusobacteria,
Anaerococcus, Peptostreptococcus and Porphyromonas was
significantly enriched in HIV-infected subjects not receiv-
ing combination anti-retroviral therapy (cART), while that
of genera including Roseburia, Coprococcus, Ruminococ-
cus, Eubacterium, Alistipes and Lachnospira was depleted
[198]. HIV-positive subjects on cART displayed similar
tendency of microbiota alterations (enrichment and deple-
tion for every genus as above-described) to those of HIV-
infected subjects not receiving cART, which were within
the intermediate magnitude of variation and were not
statistically significant relative to healthy controls [198].
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Acquired immunodeficiency can also be observed in
post-surgery patients receiving solid-organ transplantation
and administrated with immunosuppressive agents. Trans-
plant recipients were reported to have altered microbial
composition in their salivary bacterial communities as
evidenced by a rising proportion of pathobionts such as
Klebsiella, Acenitobacter, Staphylococcus, Enterococcus and
Pseudomonas [199]. Results revealed that immunosuppres-
sion did not significantly affect the dominating bacterial
taxa (i.e. Streptococcus, Prevotella) but elevated the preva-
lence or relative abundance of taxa documented as oppor-
tunistic pathogens in immunocompromised hosts [199].
Among all the immunosuppressant drugs examined, only
prednisone and mycophenolate mofetil showed a dose-
dependent association with microbial colonization of oral
cavity. In particular, prednisone dose was found to posi-
tively correlate with the prevalence of two genera Klebsiella
and Acenitobacter [199].
Conclusions
Intestinal microbiota is normally indispensable for shaping
host gut immune system and thus contributing to gut
homeostasis maintenance, and is also a key mediator in
keeping metabolic functions in the peripheral tissues in-
cluding liver and pancreas. Accumulating evidence has in-
dicated that intestinal microbiota not only induces and
reinforces pro-inflammatory immune responses but also
elicits immunosuppressive responses. Abnormal microbial-
elicited immunosuppression may result in dysregu-
lation in host metabolism and/or impairment in anti-
cancer immunity.
Data with regard to commensal bacteria have inte-
grated, which leads up to a conclusion that a number of
microbes are fluctuating on the boundary of virulence.
B. fragilis is a representative of this phenomenon. This
bacterium is able to improve the development of the
host adaptive immune system while being confined to
the lumen of the intestinal tract, but becomes entero-
toxigenic while it contingently traverses the gut epithe-
lial mucosa. Mazmanian et al [103] showed that during
colonization of B. fragilis in animals, a bacterial polysac-
charide A (PSA) was presented by DCs, which could
direct and promote the maturation of the developing im-
mune system [103]. Subsequent work by the same group
substantiated the above finding and further explored the
mechanisms of its immunomodulatory effects [129]. Not
belonging to dominant members of the gut microbiota,
B. fragilis is normally absent in conventionally raised
SPF mice. Inoculation with B. fragilis has been found to
protect mice from colitis in the T-cell-transferred and
TNBS-treated animal models. It appeared that the
purified B. fragilis PSA was sufficient to act on host
analogous to the live bacterium, including the initi-
ation of IL-10 production by Tregs, suppression of
Th17 cell production, disease protection from colitis,
and colonization of the host [129, 200]. On the other
hand, B. fragilis is capable of producing Bft (Bacter-
iodes fragilis toxin), which acts indirectly by eliciting
high levels of ROS and the ensuing damage of host
DNA [201]. Sustained high-leveled ROS, once exceeding
the host’s DNA repair capacity, may lead to DNA damage
and thereby culminating in cell death or oncogenic muta-
tions [202]. Thus B. fragilis is considered to be a risky
factor for colorectal cancer in mammals. Such example
also illustrates that a subtle balance is maintained between
mammal hosts and microbial kingdom [203].
Mucosal surface barriers are essential for host-microbial
symbiosis, the former of which are vulnerable to persistent
microbial insults and dietary antigenic components, and
must be repaired to re-establish homeostasis. Compro-
mised flexibility of the host or microbiota may place itself
on a “death tunnel” to malignancy [202]. In addition, man-
ifestations that immunotherapies are displaying efficacy in
malignancies of organs such as melanoma, bladder, renal
and lung cancers rather than cancer of the colon, the
latter being highly-populated by microbes, have garnered
extensive attention as to whether and how the microbiota
influences immunotherapy’s efficacy [202]. So the inter-
plays of microbiota and immunotherapy efficacy/toxicity
need further investigation.
Among the metabolic disorders, NAFLD, which is
characteristic of hepatic triglyceride (TG) accumulation
rather than being arisen from alcohol abuse, is linked up
with ectopic fat accumulation, especially in the liver.
T2D is characterized by persistent hyperglycemia. Patho-
physiologic mechanisms of NAFLD and T2D in com-
mon are believed to be relevant to insulin resistance,
lipotoxicity, and inflammation [171]. Insulin resistance is
a multi-organ manifestation as observed at the level of
the liver, muscle and adipose tissues. Moreover, adipose
tissues and the liver can secrete proinflammatory cyto-
kines. In addition to insulin resistance and inflammation,
other risk factors may contribute to the elevated
incidence of metabolic diseases including lifestyle (high-
fat/sugar diets and poor physical activity), gut microbiota
alterations and environmental pollutants.
Based on data heretofore, it is hypothesized that the
gut microbiota may mediate the influence of lifestyle fac-
tors triggering development of NAFLD and T2D [171].
A metagenome-wide association study on 345 Chinese
patients with T2D versus healthy individuals has revealed
that T2D sufferers exhibited a moderate degree of gut
microbial dysbiosis, referring to a dearth of some
butyrate-producing bacteria and an elevation in some
opportunistic pathogens [204]. As afore-described in
Section of “Liver diseases”, an increased prevalence of
Firmicutes, a representation of dysbiosis, is found to be
linked to NAFLD [168, 169, 205]. Of particular interest,
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these two metabolic disorders, NAFLD and T2D, to
some extent, share similar mechanisms of etiology:
being associated with dysbiosis. These novel findings
would broaden our knowledge about metabolic influ-
ences of a shifted intestinal microbiota beyond the
gut and thus benefit our exploration of therapeutic
targets for metabolic diseases.
Close to the completion of this manuscript, an inter-
esting paper has been published demonstrating the link
of atherosclerosis etiology with abnormal gut microbiota
[206]. Studies with low-density lipoprotein receptor
(LDLR) −/− mice, an atherosclerotic murine model, re-
vealed that 12-week supplementation of high-fat diet
could lead to evident aortic lesions, macrophage infiltra-
tion, and collagen level increase, concurrent with an up-
regulation of inflammatory factors [206]. This finding
suggests that gut microbiota, combined with meta-
bolisms of fatty acids and vitamin B3, could play a
profound role in the onset and development of athero-
sclerosis [206] (Fig. 3).
A growing body of novel “omics” technologies based
on next-generation sequencing, nuclear magnetic reson-
ance (NMR) spectroscopy and gas chromatography
coupled with flame ionization detector/mass spectrom-
etry (GC–FID/MS) is gaining wide popularity in the field
of cardiometabolic diseases in association with mi-
crobiota dysbiosis. The integration and comparison of
omics-mode data and molecular biological data would
offer comprehensive insight into the mechanisms by
which microbiota and metabolites thereof influence host
immunity and metabolism. Commensal microbiota in
the intestine may serve as a consortium with immunologic
and endocrine-like activities to modulate the epigenetic
status of host cells. Owing to the advances in genome-
wide epigenetic analysis, for instance, chromatin immu-
noprecipitation sequencing (CHIP-Seq), researchers can
determine and analyze these epigenetic modifications,
thereby deciphering the intrinsic intestinal microbiota–
host interactions and unraveling the impacts of microbiota
within and beyond the gut such as liver, cardiovascular
system, and even CNS.
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